Prognostic value of the Fas/Fas ligand system in breast cancer

Wspolczesna Onkologia

Volumn 17, Issue 2, 2013, Pages 120-122

  Bebenek, Marek ^a   Duś, Danuta ^b   Koźlak, Joanna ^b  

^a Regional Comprehensive Cancer Center   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Breast cancer; Fas; Fas ligand; Prognosis

Indexed keywords

FAS LIGAND;

BONE METASTASIS; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; DISEASE FREE SURVIVAL; HUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; REVIEW;

EID: 84877758441     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2013.34612     Document Type: Review

References (30)

1. Reed JC. Mechanisms of apoptosis. Am J Pathol 2000; 157: 1415-30.
2. Thorburn A. Death receptor-induced cell killing. Cell Signal 2004; 16: 139-44.
3. Knox PG, Milner AE, Green NK, Eliopoulos AG, Young LS. Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand. J Immunol 2003; 170: 677-85.
4. Rossi D, Gaidano G. Messengers of cell death: apoptotic signaling in health and disease. Haematologica 2003; 88: 212-8.
5. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-56.
6. Moller P, Koretz K, Leithauser F, et al. Expression of APO-1 (CD95), amember of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer 1994; 57: 371-7.
7. Shiraki K, Naoki T, Isselbacher KJ, Takahashi H. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci U S A 1997; 94: 6420-5.
8. Ueno T, Toi M, Tominaga T. Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res 1999; 5: 3529-33.
9. Ragnarsson GB, Mikaelsdottir EK, Vidarsson H, et al. Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells. Br J Cancer 2000; 83: 1715-21.
10. Yakirevich E, Maroun L, Cohen O, Izhak OB, Rennert G, Resnick MB. Apoptosis, proliferation, and Fas (APO-1, CD95)/Fas ligand ex - pression in medullary carcinoma of the breast. J Pathol 2000; 192: 166-73.
11. Bernstorff WV, Glickman JN, Odze RD, Farraye FA, Joo HG, Goedegebuure PS, Eberlein TJ. Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape. Cancer 2002; 94: 2552-60.
12. Sjöström J, Blomqvist C, von Boguslawski K, et al. The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin Cancer Res 2002; 8: 811-6.
13. Nagarkatti N, Davis BA. Tamoxifen induces apoptosis in Fas+ tumor cells by upregulating the expression of Fas ligand. Cancer Chemother Pharmacol 2003; 51: 284-90.
14. Botti C, Buglioni S, Benevolo M, et al. Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy. Clin Cancer Res 2004; 10: 1360-5.
15. Mann B, Gratchev A, Bohm C, et al. FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br J Cancer 1999; 79: 1262-9.
16. Hahne M, Rimoldi D, Schröter M, et al. Melanoma cell expression of Fas (APO-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274: 1363-6.
17. O'Connell J, Bennett MW, O'Sullivan GC, O'Callaghan J, Collins JK, Shanahan F: Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege. Clin Diagn Lab Immunol 1999; 6: 457-63.
18. Keane MM, Ettenberg SA, Lowrey GA, Russell EK, Lipkowitz S. Fas expression and function in normal and malignant breast cell lines. Cancer Res 1996; 56: 4791-8.
19. Mottolese M, Buglioni S, Bracalenti C, et al. Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer 2000; 89: 127-32.
20. Reimer T, Herrnring C, Koczan D, Richter D, Gerber B, Kabelitz D, Frie - se K, Thiesen HJ. FasL: Fas ratio - A prognostic factor in breast carcinomas. Cancer Res 2000; 60: 822-8.
21. Qin LX, Tang ZY. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 2002; 8: 385-92.
22. Yamana K, Bilim V, Hara N, Kasahara T, Itoi T, Maruyama R, Nishiyama T, Takahashi K, Tomita Y. Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression. Br J Cancer 2005; 93: 544-51.
23. Onodera H, Mori A, Nagayama S, Fujimoto A, Tachibana T, Yonenaga Y, Tsuruyama T. Fas/CD95 signaling rather than angiogenesis or proliferative activity is a useful prognostic factor in patients with resected liver metastases from colorectal cancer. Int J Colorectal Dis 2005; 20: 477-84.
24. Sträter J, Hinz U, Hasel C, Bhanot U, Mechtersheimer G, Lehnert T, Möller P. Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease. Gut 2005; 54: 661-5.
25. Lee WC, Yu MC, Chen MF. Prognostic impact of Fas ligand on hepatocellular carcinoma after hepatectomy. World J Surg 2004; 28: 792-6.
26. Murakami M, Sasaki T, Miyata H, Yamasaki S, Kuwahara K, Chayama K. Fas and Fas ligand: expression and soluble circulating levels in bile duct carcinoma. Oncol Rep 2004; 11: 1183-6.
27. Kanauchi H, Wada N, Ginzinger DG, Yu M, Wong MG, Clark OH, Duh QY. Diagnostic and prognostic value of fas and telomeric-repeat binding factor-1 genes in adrenal tumors. J Clin Endocrinol Metab 2003; 88: 3690-3.
28. Bebenek M, Duś D, Koźlak J. Fas and Fas ligand as prognostic factors in human breast carcinoma. Med Sci Monit 2006; 12: CR457-61.
29. Bebenek M, Duś D, Koźlak J. Fas/Fas-ligand expressions in primary breast cancer are significant predictors of its skeletal spread. Anticancer Res 2007; 27: 215-8.
30. Yoshimoto M, Sakamoto G, Ohashi Y. Time dependency of the influence of prognostic factors on relapse in breast cancer. Cancer 1993; 72: 2993-3001.